• Kazia Therapeutics appointed JPMorgan Chase Bank as sole depositary for its ADR program, replacing BNY Mellon, effective Sept. 18, 2026.
• ADSs continue trading on Nasdaq under KZIA, with each ADS representing 500 ordinary shares.
• No action required for existing ADS holders; transition expected to be seamless with no interruption to positions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-101400), on September 18, 2026, and is solely responsible for the information contained therein.